MONTREAL, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTCBB:SBFM) - Aggressive breast cancer has been traced to two key genetic culprits: the HER2 and TOP2 genes. Roche’s Herceptin drug is the standard of care for HER2 positive patients, but there is currently no therapy that targets TOP2.
